Roivant Sciences (ROIV) Liabilities from Discontinued Operations (2024)
Roivant Sciences (ROIV) posted Liabilities from Discontinued Operations of 401213000.0 for Q3 2024, up 263.4% on a QoQ basis from 110405000.0 in Q1 2024.
Roivant Sciences (ROIV) Liabilities from Discontinued Operations (2024) Analysis & Trends
Roivant Sciences' Liabilities from Discontinued Operations history runs 1 years deep, the most recent figure standing at 401213000.0 for Q3 2024.
- Quarterly Liabilities from Discontinued Operations changed N/A year-over-year to 401213000.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was 401213000.0 (changed N/A YoY) and the FY2024 annual result came in at 110405000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations was 401213000.0 for Q3 2024 at Roivant Sciences, up from 110405000.0 in the prior quarter.
- Across five years, Liabilities from Discontinued Operations topped out at 401213000.0 in Q3 2024 and bottomed at 110405000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Roivant Sciences | 24.35 Bn | 25.12 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 401.21 Mn |
| Sep 30, 2024 | 401.21 Mn |
| Mar 31, 2024 | 110.41 Mn |
| Mar 31, 2024 | 110.41 Mn |